News Headlines Article

Licensing deals add 2 blood cancer drugs to Sunesis pipeline
San Francisco Business Times

Sunesis Pharmaceuticals Inc. licensed two experimental blood cancer drugs from Biogen Idec Inc. and Takeda Pharmaceuticals’ cancer unit. Financial terms of the deals were not disclosed. Both drugs are not yet in the clinic, said South San Francisco-based Sunesis (NASDAQ: SNSS), but both were developed under a research deal between Biogen Idec (NASDAQ: BIIB) and Sunesis.